As for investors we can assume that a CR WILL happen as stated
" The financial model assumes a capital raising in FY21 of AUD15m. The amount should provide sufficient funding to undertake the Phase II trial. The financial model assumes PAT-DX1 will be licensed during this period, with the partner assuming on-going development costs. "
I will also assume that when, if, we get an announcement on licensing of PAT-DX1 this will leave us with a sp very close to 5c..............I initially did worry that a cr might be needed sooner rather than in FY21 and a CR at 2c or even 3c will do us more harm than good. I can see a concerted effort for BOD to get sp closer to 5c before embarking on a CR as at that time soooooooooooooooo much more risk would have been removed and sentiment will be 100% higher than today
LT view required
GLTA
PAB Price at posting:
2.2¢ Sentiment: Buy Disclosure: Held
